In the value-driven healthcare environment, orphan drug manufacturers are becoming increasingly aware that improving adherence requires a new approach to patient understanding and support. Take for example the required lifestyle, nutritional or physical modifications often necessary…
How well do you really know your patients? Global Genes reports that therapy adherence in the rare disease space can vary from 58 to 65 percent, a troubling statistic for our industry, and most importantly, the…
(Content Updated 5/17) CMS Protected Class Rule Finalized, Slightly Loosened for Biopharma Following CMS’ 2018 proposed rule allowing for new protected class exceptions and a comment period for stakeholders through the beginning of this year, CMS…
This article was written for Med Ad News Magazine There are many things that Americans get from outside our U.S. borders. Our top imports include oil, machines, and cars; our iTunes and Spotify accounts are stocked…
This article was written for Clinical Pathways Magazine Determining how to pay for the treatment of uncommon yet serious diseases is an important consideration in terms of sustainability and patient access. Novel and expensive therapies will…
Written for Med Ad News Magazine by Dr. Richard Stefanacci For chief medical officers (MO) of health systems, a world without Medicare rebates complicates the selection of a preferred treatment while also opening opportunities for improved…
This article was written for Journal of Clinical Pathways. Without interoperability of medical records between health systems, patients are the best chance for the medical system to provide continuity of care when medical records from a…
Over the last several years, European market demand for biosimilars has accelerated with the entry of biosimilars for many reference biologics, including high-value molecules such as adalimumab, infliximab and etanercept. However, there have been reported variations…
Biological therapies are often very expensive, putting pressure on healthcare budgets that are already restricted and potentially resulting in a decrease in patient access to treatment, in Europe biosimilar versions have been eagerly awaited in many…
Biosimilars have been eagerly awaited in many European countries to realize cost savings from the biologics budget. Gaining insight on how European decision makers are currently prioritizing these biosimilars and how they expect this to shift…
PRICENTRIC BRIEF: Universal health insurance coverage for 1.3 billion people means China must increase uptake of “clinically urgently needed new drugs” already approved in the US, EU, and Japan Mostly oncology products are being imported, along…